MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.970
+0.010
+0.34%
Closed 16:00 03/05 EST
OPEN
2.980
PREV CLOSE
2.960
HIGH
3.048
LOW
2.630
VOLUME
832.77K
TURNOVER
--
52 WEEK HIGH
4.032
52 WEEK LOW
0.6200
MARKET CAP
224.15M
P/E (TTM)
-4.3734
1D
5D
1M
3M
1Y
5Y
CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4
, /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at . The conference will be held in a virtual meeting format.
PR Newswire - PRF · 02/25 12:01
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, Feb. 24, 2021 /PRNewswire via COMTEX/ -- SEATTLE, Feb. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the...
PR Newswire - PRF · 02/24 23:30
Tyrosine Kinase JAK Inhibitors Market Study Applications, Types and Market Analysis including Growth, Trends and Forecasts 2020 to 2027 By Ameco Research
pune, India, Wed, 24 Feb 2021 00:34:52 / Comserve Inc. / -- The global Tyrosine Kinase JAK Inhibitors market size is projected to reach US$ 320630 million by...
Comserve · 02/24 05:37
End-Stage Renal Disease (ESRD) Drugs Market Size 2021 by Revenue Estimates, Capacity, Price, Gross Margin and Forecast to 2027 Research Report by Absolute Reports
Feb 23, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “End-Stage Renal Disease (ESRD) Drugs...
The Express Wire · 02/23 10:03
Relapsed Acute Myeloid Leukemia Drug Market Global Potential Growth, Share, Demand and Analysis of Key Players - Forecasts to 2020 -2027 By Ameco Research
pune, India, Tue, 23 Feb 2021 02:01:02 / Comserve Inc. / -- Relapsed Acute Myeloid Leukemia Drug market is segmented by Type, and by Application. Players,...
Comserve · 02/23 07:03
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
REDWOOD CITY, Calif., Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc....
GlobeNewswire · 02/22 14:00
Myelodysplastic Syndrome Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 22, 2021 (Market Insight Reports) -- The Global Myelodysplastic Syndrome Market is estimated to register a CAGR of over 9.5% during the forecast period...
Market Insight Reports · 02/22 12:07
End-Stage Kidney Disease Treatment Market Supply, Sales, Revenue and Forecast from 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 05:07:19 / Comserve Inc. / -- End-Stage Kidney Disease Treatment market is segmented by Type, and by Application. Players,...
Comserve · 02/22 10:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTIC. Analyze the recent business situations of CTi Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTIC stock price target is 7.70 with a high estimate of 13.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 105
Institutional Holdings: 44.77M
% Owned: 59.33%
Shares Outstanding: 75.47M
TypeInstitutionsShares
Increased
12
1.06M
New
34
5.86M
Decreased
9
2.81M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director/
Laurent Fischer
President/Chief Executive Officer/Director/
Adam Craig
Chief Financial Officer/Executive Vice President/
David Kirske
Chief Operating Officer/
Bruce Seeley
Executive Vice President/Chief Scientific Officer/
Jack Singer
Senior Vice President/
Nancy Boman
Senior Vice President/
Monique Greer
Director/
Michael Metzger
Director/
Matthew Perry
Independent Director/
David Parkinson
Independent Director/
Frederick Telling
Independent Director/
Reed Tuckson
No Data
About CTIC
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.